Icon (NASDAQ:ICLR) issued an update on its FY 2019
Pre-Market earnings guidance on Tuesday morning. The company provided earnings per share guidance of 6.81-6.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.89. The company issued revenue guidance of $2.79-2.83 billion, compared to the consensus revenue estimate of $2.81 billion.Icon also updated its FY 2020
Pre-Market guidance to 7.55-7.85 EPS.
ICLR stock traded up $1.56 during trading on Thursday, hitting $173.16. 2,623 shares of the company’s stock were exchanged, compared to its average volume of 213,955. The business has a 50-day moving average price of $166.68 and a two-hundred day moving average price of $155.44. The company has a current ratio of 2.03, a quick ratio of 2.03 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $9.15 billion, a price-to-earnings ratio of 27.49, a PEG ratio of 2.05 and a beta of 0.70. Icon has a 52-week low of $127.58 and a 52-week high of $173.00.
Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $1.74 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.74. Icon had a net margin of 13.16% and a return on equity of 24.86%. The company had revenue of $710.40 million for the quarter, compared to analyst estimates of $709.75 million. During the same period in the prior year, the firm posted $1.54 earnings per share. The firm’s revenue was up 8.5% on a year-over-year basis. On average, equities research analysts anticipate that Icon will post 6.89 earnings per share for the current fiscal year.
ICLR has been the topic of several research analyst reports. Credit Suisse Group reiterated a buy rating and set a $160.00 price target on shares of Icon in a research note on Monday, October 28th. Wells Fargo & Co began coverage on shares of Icon in a research report on Tuesday, January 7th. They issued an equal weight rating and a $180.00 price target for the company. Zacks Investment Research raised shares of Icon from a hold rating to a buy rating and set a $191.00 price target for the company in a research report on Wednesday, December 25th. Citigroup began coverage on shares of Icon in a research note on Monday, January 6th. They issued a neutral rating and a $185.00 price objective for the company. Finally, UBS Group set a $160.00 price objective on Icon and gave the stock a hold rating in a report on Friday, October 25th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of Buy and an average target price of $169.56.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Story: The risks of owning bonds
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.